Clinical trial
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With…
NCT00237627 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00237627 |
|---|---|
| Title | Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer |
| Official title | A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | PS-341, Doxil, Velcade |
| Enrollment | 107 |
| Start date | May 1, 2001 |
| Primary completion | Dec 1, 2006 |
| Completion | Jan 1, 2010 |
| First posted | Oct 12, 2005 |
| Last update posted | May 18, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: